Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)

NCT ID: NCT04358146

Last Updated: 2020-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

346 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-01

Study Completion Date

2022-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study duration is 1 month and 2 days. It is possible to add 2 additional months (optional).

The 2 first days (from D-3 to D0) correspond to the pre-selection period. These 2 days are followed by the follow-up month (from D0 to D30). It is possible to add an optional follow up of 2 months (form D30 to D90).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux in Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test

new thickened infant formula containing fibres

Group Type EXPERIMENTAL

Experimental Infant formula

Intervention Type OTHER

Exclusive formula feeding with the new infant formula thickened with fibers

Control

infant formula thickened with locust bean

Group Type ACTIVE_COMPARATOR

Infant formula thickened with locust bean gum

Intervention Type OTHER

Exclusive formula feeding with the formula thickened with locust bean

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental Infant formula

Exclusive formula feeding with the new infant formula thickened with fibers

Intervention Type OTHER

Infant formula thickened with locust bean gum

Exclusive formula feeding with the formula thickened with locust bean

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation episodes per day in average during the last 2 days,
* exclusive or predominant formula feeding
* whose parents signed informed consent

Exclusion Criteria

* preterm infants or birthweight \<2500g
* Post enteritis lactose intolerance
* Suspected or diagnosed cow's milk protein allergy requiring an eviction diet
* Use of medications that may interfere with regurgitation or gastrointestinal transit (such as alginates, laxatives, antibiotics...). All these medications have to be stopped at least 7 days before inclusion visit (V1)
* Infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject
Minimum Eligible Age

2 Weeks

Maximum Eligible Age

4 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Statitec

INDUSTRY

Sponsor Role collaborator

United Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alexandra Papadopoulou

Role: STUDY_DIRECTOR

University of Athens, Athens Children's Hospital "AGIA SOFIA"

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bastian CUMINAL

Role: CONTACT

0033155372222

ANNE-SOPHIE GARREAU

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UP2017-04-STELLAR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevention of Allergic Diseases in Infants
NCT03489733 ACTIVE_NOT_RECRUITING NA